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Intratumour heterogeneity is a major cause of treatment failure in cancer. We present in-
depth analyses combining transcriptomic and genomic profiling with ultra-deep targeted
sequencing of multiregional biopsies in 10 patients with neuroblastoma, a devastating
childhood tumour. We observe high spatial and temporal heterogeneity in somatic mutations
and somatic copy-number alterations which are reflected on the transcriptomic level.
Mutations in some druggable target genes including ALK and FGFR1 are heterogeneous at
diagnosis and/or relapse, raising the issue whether current target prioritization and molecular
risk stratification procedures in single biopsies are sufficiently reliable for therapy decisions.
The genetic heterogeneity in gene mutations and chromosome aberrations observed in deep
analyses from patient courses suggest clonal evolution before treatment and under treatment
pressure, and support early emergence of metastatic clones and ongoing chromosomal
instability during disease evolution. We report continuous clonal evolution on mutational and
copy number levels in neuroblastoma, and detail its implications for therapy selection, risk
stratification and therapy resistance.
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Neuroblastoma is the most common solid paediatrictumour, accounting for 15% of cancer-related deaths inearly childhood. Especially patients directly diagnosed
with high-risk neuroblastoma have a poor prognosis1,2. High-risk
(HR) and ultra-high-risk (UHR) neuroblastoma are characterised
by active telomere maintenance and mutations in distinct path-
ways defining specific clinically relevant molecular risk
classifiers3. Telomere maintenance as the hallmark of the UHR
concept is either conveyed by TERT gene activation due to
TERT promoter mutations, TERT re-arrangements or high
MYCN expression or by alternative lengthening of telomeres
(ALT)4. Intriguingly, even high-risk neuroblastomas initially
respond to treatment, but eventually relapse as chemotherapy-
resistant disease. Current target prioritisation efforts in
relapsed/refractory patients such as INFORM, MAPPYACTS,
NCI-COG MATCH, PROFYLE or ITHER5–8 rely on mole-
cular profiling based on bulk sequencing approaches in single
tumour biopsies. Targeted therapy based on single-biopsy
profiles is often inefficient or only exhibits short-term effects,
and rarely results in long-term tumour control. Secondary
resistance following promising short-term efficacy is clinically
observed in particular for activating ALK mutations, the most
recurrent actionable single-nucleotide variant (SNV) present
in neuroblastoma for which targeted inhibitors of 1st, 2nd and
now 3rd generation have entered clinical trials9–12. These
clinical observations indicate the existence of therapy-
resistant subclones in high-risk neuroblastoma. Indeed, neu-
roblastoma shows extensive genetic intratumour heterogeneity
and distinct evolutionary patterns13–15. Both linear/late-
branching as well as parallel/early-branching evolution occurs
in neuroblastoma, and impacts clinical behaviour differently,
with early branching being associated with adverse outcome14.
Thus, intratumour heterogeneity is an important feature of
neuroblastoma, which deserves in-depth analysis and further
interpretation with respect to potential clinical implications.
While neuroblastoma typically has few SNVs, neuro-
blastoma genomes show pronounced somatic copy-number
alterations (SCNA)16. Chromosomal instability describes the
progressive accumulation of SCNAs over time, equating to
changes in the number and structure of chromosomes during
tumour evolution. Chromosomal instability results from
chromosome segregation errors during cell division, and high
levels have been linked to poor prognosis17,18 and multi-drug
resistance19,20 in many solid tumours. Neuroblastoma is
widely considered to be driven by chromosomal instability
since high levels of multiple clinically relevant SCNA events
occur with a low overall mutational burden. Focal amplifica-
tions of the MYCN oncogene, re-arrangements within the
TERT locus on chromosome 5p and SCNAs on chromosomes
1p36, 11q and 17q, genetically define a high-risk clinical
phenotype4,21,22. Despite the clinical relevance of chromoso-
mal instability in neuroblastoma and recent evidence in other
cancers that ongoing chromosomal instability keeps shaping
cancer genomes during disease progression23–25, the extent of
ongoing chromosomal instability after initial biopsy at diag-
nosis and the dynamics of SCNA acquisition during neuro-
blastoma progression and treatment remain unclear.
To address open questions about neuroblastoma intratumour
heterogeneity, we combine multi-region transcriptome and
whole-exome sequencing, followed by ultra-deep targeted
sequencing of 140 spatially and temporally separated tumour
samples from 10 clinically heterogeneous patients with neuro-
blastoma. We describe spatial and temporal intratumour het-
erogeneity of actionable mutations and distinct patterns of
tumour evolution based on SNVs and SCNAs.
Results
Analysis of SNVs in spatially and temporally distinct neuro-
blastoma samples reveals extensive intratumour heterogeneity.
To analyse neuroblastoma heterogeneity within the tumour tissue
and across the course of disease in individual patients, we per-
formed genomic and transcriptomic analysis of multiple spatially
and temporally distinct samples per patient. We performed
whole-exome sequencing (WES, N= 51 biopsies), targeted
sequencing (N= 140 biopsies) and RNA sequencing (N= 48
biopsies) from 10 patients at the age of 0.5–14 years (3 girls and 7
boys) treated for neuroblastoma at the Charité Berlin, according
to the German NB2004 trial and NB Registry 2016 protocols
(Fig. 1 and Supplementary Fig. 1). Seven of the ten patients had a
high-risk, 1 child an intermediate-risk and 2 patients a low-risk
disease according to INRG/INSS classification. Between 2 and 10
biopsies per patient were analysed by WES (Fig. 1). For 3 patients,
samples from 2 different time points were included. Samples were
biopsied from primary tumours at diagnosis (N= 17), after 4–6
cycles of induction chemotherapy at tumour resection (N= 26)
or at diagnosis of relapse (N= 8). Primary (N= 45) and meta-
static tumour sites (N= 6) were biopsied (Fig. 1). To increase the
sensitivity for SNV and SCNA detection, tumour regions with a
high tumour purity (>60% for WES and RNA sequencing) were
macrodissected from sequential sections. Matched normal blood
controls were collected once from each patient at diagnosis. SNVs
and SCNAs were called from WES data. To assess the clonality of
SNVs detected with WES at higher resolution, we performed
ultra-deep targeted sequencing (mean coverage 2500×). To this
end, following WES analysis of 51 samples, we included further
89 samples analysing a total of 140 samples by ultra-deep targeted
sequencing of 1479 WES-detected SNVs.
Consistent with previous reports3,4,21,26, the total number of
somatic, non-silent SNVs varied between 0 and 60 (median: 15)
per sample (Fig. 1c). As expected, low-risk neuroblastomas had
significantly fewer non-silent mutations than high-risk neuro-
blastomas (p= 9 × 10−5, two-sided Wilcoxon test)3,10,21. For
each patient, SNVs were categorised as “clonal” if detected in all
samples from that patient or “subclonal” if detected in a subset of
samples from that patient or “subclonal/specific” if exclusively
detected in one sample (Fig. 1c). The proportion of clonal SNVs
varied from 0 to 87% among samples (average over patients:
37%), while on average 22% of mutations in each sample were
categorised as subclonal/specific (Fig. 1c), pointing towards
significant intratumour heterogeneity. SNVs were considered to
be clonal if present with a variant allele frequency (VAF) greater
than 10% in WES or targeted sequencing data in all samples. This
threshold was chosen to avoid overestimation of heterogeneity.
All other detected SNVs were considered subclonal. Roughly 45%
of SNVs were clonal, irrespective of whether the SNVs were
silent, non-silent or were detected within cancer-related genes
(Supplementary Fig. 1b and Supplementary Data 1). For the large
majority of SNVs (87.9%), assignment as clonal or subclonal were
consistent between WES and targeted sequencing datasets
(Supplementary Fig. 1c). As expected, the overall proportion of
SCNAs markedly differed among patients. In line with previous
reports, MYCN amplification, a hallmark of high-risk neuroblas-
toma, showed little variation between spatially distinct samples,
but pronounced differences in patient CB1003 between time
points (Fig. 1c). Our data demonstrate extensive spatial and
temporal genetic heterogeneity across distinct neuroblastoma
biopsies from the same patient in our cohort.
Spatial and temporal heterogeneity of single-nucleotide var-
iants affects therapeutically actionable genes in neuroblastoma.
To determine biologically and potentially clinically relevant
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genetic intratumour heterogeneity, we assessed non-silent SNVs
in known cancer-related genes (Fig. 2). Whereas between two and
six non-silent SNVs were detected in 801 selected known cancer-
related genes (Supplementary Data 1 and Supplementary Table 2;
defined by the COSMIC database27 and other studies8,10,16,28) in
high-risk tumours, very few or no non-silent SNVs in the selected
cancer-related genes were detected in neuroblastomas from other
risk groups (Fig. 2a). Most SNVs were detected in all samples
(Fig. 2a) from a given tumour, indicating the clonal presence and
early evolutionary emergence. Known pathogenic mutations in
HRAS were among these clonal mutations, and a clonal ALK
mutation was detected in patient CB1003. However, some
detected mutations appeared spatially and/or temporally hetero-
geneous (e.g. ALK R1275Q in patients CB1002 and CB1008, as
well as FGFR1 in patient CB1002, Fig. 2a). The persistence of
clonal mutations in ATM, PTK2, GLI3 and CLTCL1 in all tumour
locations analysed in samples from diagnosis and at relapse in
patient CB1002 (Fig. 2b) could indicate the relevance of these
SNVs for tumour progression. In contrast, high overall numbers
of de novo SNVs and mutations in the druggable genes, ALK,
BRAF and FGFR1, were only detected in a subset of relapse
samples from patient CB1002 compared to the primary tumour at
diagnosis (in line with previous studies reporting an increase in
mutational burden and de novo MAPK pathway mutations in
relapsed neuroblastoma26,29). The high degree of spatial hetero-
geneity observed for SNVs in druggable target genes is exempli-
fied by the ALK R1275Q mutation only being detected in 2 of 7
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Fig. 1 Study design and overview of neuroblastoma intratumour heterogeneity determined in 10 patients from multi-region WES and targeted re-
sequencing. a Representative picture of a neuroblastoma (arrows indicate spatially separated samples for analysis). b Study design and sample workflow. c
Oncoplot outlining patient/sample characteristics and WES results from 51 neuroblastoma samples collected from 10 patients (CB1001 – CB1010).
Columns correspond to individual samples. Gained regions are indicated in blue, lost regions are marked in red. Risk stratification determined patient risk at
diagnosis as high (HR), intermediate (IMR) and low (LR) according to current practice. Patient outcomes are indicated, including death of disease (DOD)
and complete remission (CR), with CR being >3 years for this cohort. SNV, non-synonymous single-nucleotide variants; SCNA, somatic copy-number
alteration, clonal, present in all samples; subclonal, present in >1 sample from 1 single patient; subclonal (specific), present in a single biopsy.
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only 3 of 7 locations and the FGFR1 N557K mutation in only 5 of
7 locations. This detailed picture of spatial heterogeneity in
actionable target genes in patient CB1002 points to a potential
reliability problem for the current routine practice of target
identification by single biopsy- and bulk sequencing-based
molecular tumour profiling as this profile may not accurately
describe the disease in the patient. Spatial heterogeneity with
specific mutations in the cancer-relevant genes, FGFR1, ALK and
ATM, among others, was also detected in other patients in our
cohort supporting that the spatial heterogeneity in druggable
a











































































































































































Fig. 2 ITH of SNVs in cancer-related genes analysed by WES and ultra-deep targeted sequencing. a Heatmap showing mutations in known cancer-
relevant genes, based on WES of 51 tumour samples from 10 patients (CB1001 to CB1010). The frequency of mutated compared to wild-type alleles (VAF)
is depicted in a blue colour code. Cancer-related genes connected to neuroblastoma genetics are marked in red. Single-nucleotide variants (SNVs)
detected at separate positions in the gene are listed twice. Each column corresponds to an individual sample with samples from the same patient grouped
next to each other. Clinical characteristics of patients and samples are annotated below. For 3 patients (CB1003, CB1008, CB1009), samples from different
time points (Time) were analysed for the primary tumour site, distant metastasis or metastatic infiltration (Site). DOD: death of disease, CR: complete
remission, HR: high risk, IR: intermediate risk, LR: low risk, MYCN:MYCN amplification. VAF of somatic SNVs based on targeted sequencing data from two
exemplarily shown patients, CB1002 (b) and CB1003 (c). Only SNVs detected in one or more samples are displayed as one column per SNV. Mutations in
cancer-related genes are explicitly named, and were indicated as clonal (VAF > 10% in all samples from a tumour, green triangles) in comparison to
subclonal oncogenic mutations (red triangles). Row numbers identify samples at distinct time of biopsy collection within the disease course. Columns
adjacent to the right of heatmaps indicate further characteristics. Samples denoted with WES were already included in the exome sequencing data.
Samples denoted with FFPE were formalin-fixed and paraffin-embedded before analysis was performed, all other samples were fresh-frozen biomaterial.
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targets clearly presented in the case of patient CB1002 is likely not
a rare exception, creating the need to re-evaluate targeted therapy
decision-making.
In another example, the actionable ALK R1275Q mutation was
observed at high variant allele frequency at diagnosis, but not
detectable by WES after chemotherapy in patient CB1008
(Fig. 2a). Targeted ultra-deep sequencing, however, was able to
recover this mutation in the sample after therapy, albeit at very
low allele frequency (Supplementary Fig. 2f). This was further
validated by a droplet digital PCR (ddPCR) assay confirming high
VAF of the ALK R1275Q at diagnosis but loss of the mutation in
8 out of 10 samples from the resection (Supplementary Fig. 3). A
mutation in the KIF1B tumour suppressor was detected (WES)
only after chemotherapy in patient CB1008, which was confirmed
by targeted ultra-deep sequencing, suggesting that this mutation
occurred de novo during therapy (Fig. 2a and Supplementary
Fig. 2f). Finally, clonal expansion of a mutation after therapy was
also observed in a subset of cases, such as the DPYSL530 mutation
in patient CB1003 (Fig. 2c). We conclude that actionable and
pathogenic SNVs are spatially and temporally heterogeneous in
neuroblastoma, revealing clonal evolution prior to and under
selective treatment pressure with potential implications for
targeted therapy decisions.
High degrees of spatial copy-number heterogeneity and
ongoing chromosomal instability detected in a subset of neu-
roblastomas. To investigate the degree of ongoing chromosomal
instability in neuroblastoma, allele-specific SCNAs were called
from WES data for all 51 samples from the 10 patients. Quality
control revealed a low signal-to-noise ratio in patient CB1006,
and this patient was excluded from further analyses, yielding a
final set of 48 samples from 9 patients. Allele-specific SCNA
profiles underwent reference phasing, phasing-based correction of
copy-number states and detection for structural parallel evolution
using refphase as previously described23. The phased and cor-
rected allele-specific SCNA profiles included information on
subclonal SCNAs derived from opposite alleles as mirrored sub-
clonal allelic imbalances (MSAI) and were subjected to tree
reconstruction using MEDICC231,32, including reconstruction of
the most recent common ancestor to detect early events prior to
clonal diversification.
To allow for consistent comparison of SCNA events across
patients, SCNAs were aggregated on a per-cytoband level and
stratified into clonal (present in all samples from that patient) and
subclonal (present in some samples from that patient) events.
Strong heterogeneity was detected on the level of SCNAs across
the cohort. Across the cohort, between 13 and 92% (median 34%,
mean 42%) of the genome of each patient’s cancer was affected by
at least one SCNA event in at least one sample (Fig. 3a and
Supplementary Fig. 4). We detected subclonal SCNA events in
every patient, with a median of 57 segments affected by subclonal
SCNA events compared to 132 clonal events. The majority of
SCNAs were clonal for most patients (CB1001, CB1002, CB1007,
CB1009 and CB1010), indicating early structural evolution
followed by relative stasis. Contrary to this, a similar number of
clonal and subclonal SCNAs were detected in patients CB1003,
CB1004 and CB1005, demonstrating ongoing clonal evolution
and chromosomal instability (Table 1). Patient CB1008 showed a
disproportionally large number of subclonal, compared to clonal
events, indicative of strong clonal diversification and ongoing
chromosomal instability between samples obtained at diagnosis
and at tumour resection after first cycles of induction therapy.
This patient showed repeated copy-number neutral loss of
heterozygosity (LOH) events in large areas of the genome
(chromosomes 7–9, 12, 14–16, 17 and 19) only in the tumour
resection samples, while sharing the clinically relevant SCNA
events, LOH of 1p and MYCN amplification, among diagnostic
and resection samples. Across the cohort, aggregated SCNA
profiles show clear non-uniformity along the genome (Fig. 3)
with hotspots in the clinically relevant regions, 1p36 (clonal LOH
or clonal gain events in 8 of 9 patients), 11q (clonal LOH or gains
in 5 of 9 patients) and 17q (clonal gain events in 8 of 9 patients).
Interestingly, even though MYCN amplifications were detected in
only 3 of 9 patients, we observed clonal gains of 2p24 in 6
additional patients, making the MYCN locus the most frequently
gained region in our cohort even in low- and intermediate-risk
patients. In line with previous reports33, subclonal or clonal gains
of chromosome 7q were detected in 8 of 9 patients. We also
detected repeated MSAI events in 3 of 9 patients (Fig. 4)
indicative of parallel evolution, but a low sample size prevented
assessment of statistical significance.
The clinical importance of SCNAs in neuroblastoma strongly
depends on the size of the events. Segmental SCNAs generally
confer a poor prognosis whereas whole-chromosome gains and
losses are considered neutral towards patient outcome34–36. To
explore this, we stratified chromosomes into unchanged (diploid),
whole-chromosome altered and segmentally altered chromo-
somes, and separately tallied their fractions in each category for
each patient (Fig. 3b). The majority of chromosomes were
affected by segmental duplications in most patients. In two
patients (CB1007 and CB1009), however, most chromosomes
were instead affected by whole-chromosome gains and losses
(Fig. 3b). Patients CB1007 and CB1009 were the only low- and
intermediate-risk patients in our cohort for whom SCNA data
was available, confirming prior observations about the clinical
relevance of segmental versus whole-chromosome SCNAs in
neuroblastoma37,38. In summary, SCNAs are highly spatially and
temporally heterogeneous in neuroblastomas, and in some cases
are continuously acquired, indicating ongoing chromosomal
instability.
Inference of evolutionary trajectories allows relative timing of
the emergence of the metastases in neuroblastoma evolution.
We next investigated each patient individually for evidence of
early clonal diversification by inferring clonal hierarchies from
variant allele frequency-based SNV clustering. We observed both
linear (CB1003) and branched (CB1002) hierarchies in high-risk
patients (Fig. 4a), supporting variable subclonal diversification
during high-risk disease. Clonal evolution based on successive
mutation acquisition in different spatial and temporal samples
from each patient led to between three and eleven genetically
distinct subclonal branches and lineages (clone numbers in circles,
Fig. 4a). In some cases, samples from a patient (numbers at the
lineage ends, Fig. 4) are assigned to different subclonal lineages
indicating that the biopsy sample harboured multiple subclones
(i.e. samples 14, 15 from CB1002). This clonal intermixing of
subpopulations within one sample illustrated the extensive spatial
and temporal genetic heterogeneity in our cohort (Fig. 4a). In 7
out of 8 cases for which both SNV and SCNA data were available,
tumour phylogenies based on SCNA profiles agreed with the
hierarchies inferred from SNVs (Fig. 4 and Supplementary Fig. 4).
In CB1005 the SNV and SCNA topologies did not agree. Here the
SCNA phylogeny groups the dominant clones of samples 12 and
17 as well as those of 11, 13 and 14 into a monophyletic clade
(Supplementary Fig. 4). Ancestral reconstruction using MEDICC2
provided additional evidence in support of this topology, includ-
ing a gain on chromosome 6q shared between 12 and 17 and an
additional gain on 7q shared between 11, 13 and 14. The analysis
also revealed multiple parallel events, including MSAI on chro-
mosomes 1q and 18p and 18q. We next compared samples from
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primary and metastatic tumour sites. CB1001 is a patient with
high-risk disease that includes a clonal MYCN amplification, and
for whom 5 SCNA profiles were available comprising 4 regions
from the primary tumour and 1 from a metastatic renal infiltra-
tion. This metastatic infiltration probably occurred not by
hematogenous dissemination but by aggressive outgrowth of the
primary tumour. Limited heterogeneity at both SCNA and SNV
levels occurred in the CB1001 primary tumour sites, and most
alterations were clonal (Fig. 4b). Both SCNA and SNV data
indicated branching of the metastatic clone prior to the emergence
of the clones in the primary (Fig. 4b, c and Supplementary Fig. 2a).
This “early” branching is clearly evidenced by parallel evolution
between the primary and metastatic clades: chromosome 9 har-
boured an MSAI event in which a single additional copy of 9q was
gained in both primary and metastatic samples, but the copies
originated from different parental chromosomes (haplotypes)
in the metastatic infiltration and primary tumour (Fig. 4e). In
addition, all biopsies from the primary tumour also harboured an
~2.5 mb focal LOH deletion event on chromosome 6q, which was
absent in the metastatic infiltration (Fig. 4d). Since lost genetic
material cannot be regained, this clearly indicates the branching of
the metastatic clone before the diversification of the primary
samples. The tree topology additionally showed high robustness as
measured by jackknife resampling of the underlying SCNA data
(Fig. 4c). A similar pattern emerged in patient CB1003, from
whom 10 samples were available (5 biopsies at diagnosis, 4 from
the resected tumour and 1 synchronously resected lymph node
metastasis). SCNA phylogeny clearly separated the two time
points (Fig. 4g) and showed a dynamic acquisition of additional
MYCN copies during disease progression (Fig. 4h and Supple-
mentary Fig. 5). Multiple single-copy gain events occurred on
2p24 in the primary tumour at diagnosis that developed into a
MYCN amplification (16 copies) at the time of tumour resection
(Fig. 4f, g, h and Supplementary Fig. 5). An intermediate level of
MYCN gain, estimated at 6 copies, was detected in the metastasis
(Fig. 4h), indicating the initial 2p24 gain occurred early in tumour
evolution, followed by additional 2p24 gains in the primary
tumour and the metastasis, likely due to increased accumulation of
MYCN in circular extrachromosomal DNA elements, as recently
described39–41. Interestingly, chromosome 5q contained a single-
copy gain event clonal in all samples but the metastasis. Two
hypotheses are thus supported by the data: (i) emergence of the
metastasis before diversification of all primary samples followed






























































































































































Fig. 3 Intratumour heterogeneity of somatic copy-number alterations in the neuroblastoma cohort. a Overview of Somatic copy-number alterations
(SCNA) events per-cytoband aggregated across 9 patients. Amplifications and gains are visible in the upper half, loss of heterozygosity (LOH) and deep
losses in the lower half of the plot. Clinically relevant chromosome regions 1p36, 2p24, 11q and 17q are highlighted in red at the top. Mirrored subclonal
allelic imbalances (MSAI) are indicated by grey shading.MYCN locus: 2p24 b Fraction of chromosomes affected by segmental or whole-chromosome gains
and losses are depicted for the low-and intermediate-risk patients (CB1007, CB1009) and the high-risk patients (CB1001, CB1002, CB1003, CB1004,
CB1005, CB1010).
Table 1 Clonality of somatic copy-number alterations identified in distinct neuroblastoma samples during the course of disease in
9 patients.
Patient Risk group # Clonal segments (%
genome)
# Subclonal segments (%
genome)
Biopsied samples # Samples MNA
CB1001 HR 100 (12%) 3 (0.4%) Tumour resection 5 Yes
CB1002 HR 644 (79%) 105 (13%) Diagnosis of relapse 5 No
CB1003 HR 54 (7%) 57 (7%) Neuroblastoma diagnosis + tumour
resection
10 Yes
CB1004 HR 104 (13%) 100 (12%) Tumour resection 3 No
CB1005 HR 132 (16%) 98 (12%) Tumour resection 5 No
CB1007 LR 487 (60%) 17 (2%) Neuroblastoma diagnosis 2 No
CB1008 HR 24 (3%) 353 (44%) Neuroblastoma diagnosis + tumour
resection
6 Yes
CB1009 IMR 561 (69%) 1 (>0%) Neuroblastoma diagnosis + tumour
resection
9 No
CB1010 HR 247 (30%) 33 (4%) Diagnosis of relapse 3 No
HR high-risk, IMR intermediate risk, LR low risk, MNA MYCN amplification.
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the emergence of the clone in the biopsy samples but before
diversification of the resection samples (Fig. 4) implicating a
secondary loss of 5q in the metastatic branch. Tree reconstruction
with MEDICC2 inferred option (ii) as the more parsimonious
(Fig. 4) and jackknife robustness analysis of the tree indicates a
62% support for the metastatic split between biopsy and resection
samples. In any case, all samples obtained from the resected
tumour showed clear allelic imbalance and a single-copy gain of
chromosome arm 9q, which was absent in both the diagnostic
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primary tumour (Fig. 4i), confirming additional events and
ongoing evolution after biopsy and metastatic dissemination.
Thus, SCNA analysis indicates high genomic divergence between
primary tumour and metastases in neuroblastoma suggesting that
metastases spread early in disease evolution from the primary
tumour site, although additional studies are required to further
substantiate this.
Gene expression is temporally but not spatially heterogeneous
in neuroblastomas. To detect phenotypic heterogeneity in spa-
tially and temporally distinct neuroblastoma samples, high-
coverage paired-end messenger RNA sequencing was performed
on 48 of 51 samples and gene expression was quantified
(Figs. 1b, 5a and Supplementary Fig. 6). Genes known to be
specifically expressed in neuroblastoma, such as HAND2,
PHOX2B, and DBH, were homogeneously expressed across all
samples, indicating that the proportion of mRNA derived from
neuroblastoma cells was equally distributed between each sample.
RNA expression analysis confirmed the impact of the most fre-
quent copy-number changes over time in the cohort, i.e. the
MYCN amplification, and revealed a clear correlation between
MYCN copies and gene expression of MYCN and of its target
gene TERT. Other SCNAs also clearly correlated with changes in
gene expression, such as the gain in chr 7, which was detected in 8
out of 9 patients and which led to an increase of expression of the
IL6 gene located on chr. 7p15.3 (Supplementary Fig. 6a). To
further address the consequences of temporal ITH of SCNAs, we
performed Gene-Set Enrichment Analysis (GSEA) of known
downstream targets of MYCN42 (Supplementary Data 2) for
patients CB1003 and CB1008. In CB1003, we found MYCN-
regulated genes enriched towards the tumour resection in line
with the acquisition of the MYCN amplification at that time
point. In CB1008, MYCN-regulated genes were significantly
enriched towards diagnosis, in agreement with the decrease of
MYCN copy number during tumour progression (Supplementary
Fig. 6b). Based on bulk RNA-seq data, temporal expression
changes between diagnostic versus tumour resection did not
include a significant shift in differentiation state-related sig-
natures i.e. mesenchymal versus adrenergic signatures43 (Wil-
coxon test p-values > 0.05) (Supplementary Fig. 6c). A principal
component analysis (PCA) utilising expression levels of the most
variable genes confirmed that interpatient differences dominated
over intratumour heterogeneity in gene expression (Supplemen-
tary Fig. 6g and Supplementary Data 4). A different picture
emerged when PCA was restricted to genes previously used for
expression-based classification between high- and low-risk
neuroblastomas44 (Supplementary Data 3). Low- and high-risk
tumours in our cohort were clearly separated, as expected, but
two sets of samples collected at different time points in three
patients were also clearly separated (Fig. 5a). In patient CB1003,
samples from the diagnostic biopsy clustered with low-risk
Fig. 4 Primary and metastatic tumour evolution inferred by genetic analysis of clonality. a Single-nucleotide variant- (SNV)-based phylogenetic trees
depict variable clonal diversification. Branch lengths correspond to the total numbers of SNVs. Branch colours represent different subclones. Numbers at
the end of each branch indicate samples containing all clones (numbers in circles) of the branch and its ancestor clones. Samples were collected at
diagnosis (orange), at tumour resection (red) and at diagnosis of relapse (turquoise). Metastatic samples are indicated by asterisks. A deeper data
showcase is provided for patient CB1001, showing SNV- (b) and somatic copy-number alteration- (SCNA)-based trees (c). d SCNA plots from sample 15
(rainbow) showing a loss of heterozygosity (LOH) event on chromosome 6q that is absent in the metastastic sample 11 (green). e SCNA plots from the
metastatic sample 11 (green shaded) and primary tumour sample 15 (rainbow) showing an mirrored subclonal allelic imbalances (MSAI) event on
chromosome 9. SNV tree (f) compared to SCNA phylogeny (g) in CB1003. Time point or spatial position is indicated by shading, none (metastasis), grey
(biopsy at diagnosis) and green (tumour resection). h Dynamic acquisition of additional copies of the MYCN locus on chromosome 2p. i Monoallelic gain
on chromosome 9q in the tumour resection samples. (green) but not in the metastatic clone.








































































Fig. 5 Impact of temporal and spatial intratumour heterogeneity on gene expression, ultra-high-risk stratification and putative therapy options. a RNA
sequencing was used to analyse gene expression in 48 spatially and temporally distinct samples from a cohort of 10 patients. Principal component analysis
(PCA) was conducted for risk-associated gene expression in the 48 samples. Legend describes patient number and sampling time. Arrows within the plot
indicate samples from patients CB1003 and CB1008 collected at different time points during the disease. Arrows adjacent to the axis annotate high-risk
and low-risk/intermediate-risk neuroblastomas. b Molecular classification of ultra-high risk (UHR) for the patient (termed UHR diagnosis here) was
performed for each tumour sample separately using TERT mRNA expression, MYCN copy number and mutations (WES) in the TP53 and RAS/MAPK
pathways. Variant allele frequency (VAF) is given for all mutations as % of reads that support the mutation. Mutations in the TP53/RAS/MAPK pathways
with a VAF > 5% were defined as UHR mutations. Other druggable mutations based on the INFORM criteria8 are shown for each sample. TERT expression
was defined as “high” according to Ackermann et al.3.
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tumours, while the samples from the resected tumour clustered
with high-risk samples, suggesting therapy-induced changes in
the expression of risk-associated genes (Fig. 5a). Our data
demonstrate that gene expression programmes in neuroblastomas
clearly follow temporal heterogeneity in SCNA and can change
significantly under therapy.
Temporal and spatial genetic neuroblastoma heterogeneity in a
patient affects clinical assessment of ultra-high risk and
second-line therapy options. We and others have recently
described molecular determinants of clinical UHR stratification3.
This UHR stratification is based on (i) the presence of telomere
maintenance via TERT rearrangement, MYCN-amplification,
high TERT expression, or ALT and (ii) mutations in TP53 and
RAS/MAPK pathways. We observed high spatial intratumour
genetic heterogeneity and subclonal evolution in our patient
cohort that affected these UHR determinants (Figs. 1–4) and
hypothesise that clinical risk stratification may be affected by this
genetic heterogeneity. To test this, we performed molecular-based
risk stratification on each of the neuroblastoma biopsies sepa-
rately using the information on TERT mRNA expression, MYCN
copy number and TP53/RAS/MAPK pathway mutations from
WES data. Based on these molecular risk factors, almost one third
(29%) of biopsies (15 of 51) were classified as UHR (Fig. 5b). In
line with our hypothesis, not all biopsies from the same patients
were classified homogenously. Whereas biopsies collected at
diagnosis in patient CB1003 were not classified as UHR, all
biopsies from the primary tumour resected after induction ther-
apy were classified as UHR (Fig. 5b). This suggests the clonal
selection of UHR subclones during therapy. In contrast, diag-
nostic biopsies from patient CB1008 (currently in complete
remission for >3 years) were classified as UHR, while biopsies
after chemotherapy at tumour resection were not classified UHR.
Most prominently, this occurred due to longitudinal changes in
MYCN copy number (CB1003) or ALK mutation as well as TERT
gene expression (CB1008). In total, 2 out of 10 patients showed a
heterogeneous UHR profile. This is important because the neu-
roblastoma community is currently discussing to base alternative
experimental therapy decisions on the presence of druggable
mutations and UHR classification at diagnosis in the future, but
our data clearly show that a subset of UHR patients still benefits
from standard high-risk treatment. We conclude that clonal
evolution in neuroblastoma can influence the molecular profile
within the tumour, across disease sites and/or during the course
of disease in potentially clinically relevant ways. Our findings
support the consideration of strategic and methodological chan-
ges for target identification and molecular risk classification as
well as subsequent treatment decisions in individual patients with
neuroblastoma.
Discussion
Intratumour heterogeneity is considered a major cause of cancer
progression and treatment resistance24. Multi-region sequencing
studies have characterised the extent of intratumour hetero-
geneity in a variety of cancer entities, and linked the evolutionary
subtypes with patient outcome24,35,45,46. Our present multi-
region sequencing study of 10 patients with neuroblastoma shows
extensive spatial and temporal intratumour heterogeneity that
also affected genes encoding actionable targets, such as ALK and
FGFR1, thus, harbouring potential implications for therapeutic
target selection. Analysis of phased SCNAs revealed early emer-
gence of the metastatic lineage and ongoing chromosomal
instability, including the appearance of a MYCN amplification
later in the course of disease. This process of clonal evolution led
to clinically relevant changes in molecular risk stratification in
some patients.
Our in-depth analysis of SNVs and SCNAs assessed a sig-
nificantly lower number of SNVs, and practically no mutational
hits in cancer-related genes in low- and intermediate-risk neu-
roblastomas. Overall, we detected a low number of non-silent
SNVs (range 0–60, median 15), which is in accordance with
previous reports3,4,26. Less than half of the detected SNVs were
clonal, based on our criteria for clonal appearance (present in all
samples from a patient with VAF > 10%). To gain insight into the
biological and clinical relevance of intratumour heterogeneity, we
focused our analysis on non-silent SNVs in cancer-related genes.
Non-silent SNVs (2–6 per tumour) in cancer-related genes
(HRAS, ALK and ATM) occurred exclusively in high-risk neu-
roblastomas and were clonal in a subset of patients but also
spatially or temporally heterogeneous in others.
Efficacy of a targeted therapy that might be included into
second-line treatment for a patient with neuroblastoma depends
on precise and reliable diagnostics. We detected spatially het-
erogeneous SNVs in genes encoding actionable targets (FGFR1
N577K, BRAF V600E and ALK R1275Q) or temporally hetero-
geneous SNVs in CCND3 or NOTCH2. Spatially heterogeneous
mutations suggest that current diagnostic biopsies may miss or
overestimate therapeutically actionable alterations. More specifi-
cally, application of current target prioritisation algorithms might
have obtained different results when analysing different tumour
locations, such as relapse tumour samples from our patient
CB1002, which harboured different private druggable mutations.
Most importantly, even the presence of activating ALKmutations,
the most frequent actionable alteration in neuroblastoma9,35,47
for which targeted therapies are currently being clinically
tested48–53, was spatially and temporally heterogeneous. Such
heterogeneity could impact the clinical interpretation of diag-
nostic biopsies and may obscure reasons for nonresponse to ALK
inhibitor therapy in patients in whom the majority of the tumour
cells do not contain activating ALK mutations54. Our finding that
druggable mutations are spatially and temporally heterogeneous
demonstrate that clonal neuroblastoma evolution has potential
implications for targeted therapy decisions. We postulate that for
a subset of patients, bulk sequencing at a single tumour location
might sometimes lead to an imprecise molecular diagnosis,
potentially leading to the wrong choice for targeted therapy. In
the future, the technological advances of single-cell technologies
and liquid biopsies might contribute to solve this problem, as
repeated multi-region sequencing of tumour tissue is not feasible
in the clinical routine.
Allele-specific SCNA profiling and multi-region phasing based
on WES data revealed substantial heterogeneity in neuroblastoma
chromosomal instability in patients in our cohort. Subclonal
SCNAs were observed in every patient and 3 out of 9 patients
showed evidence of parallel evolution through detection of MSAI
events. Most SCNAs were numerical chromosomal aberrations in
the two patients with low- and intermediate-risk disease, corre-
lating with previous reports37,38. In most patients (5 of 9), the
majority of the SCNAs were clonal, demonstrating the early
appearance of SCNAs in the course of disease. Interestingly, in
one patient with mostly clonal SCNAs, extensive intratumour
SNV heterogeneity was detected, suggesting that in this patient
SCNAs were the tumour-driving force followed by subclonal
mutational diversification. In the remaining patients, variable
degrees of ongoing clonal evolution and chromosomal instability
occurred. Strong temporal heterogeneity was observed in one
patient (CB1008) with many subclonal SCNAs and ongoing
chromosomal instability between samples collected at initial
diagnosis or after therapy, but stable detection of a MYCN
amplification and loss in 1p36 both at neuroblastoma diagnosis
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and following therapy. The heterogeneous profile of cancer-
related gene mutations in the same patient showed the near
elimination of an initial ALK R1275Q mutated clone after ther-
apy, further corroborating the extensive temporal heterogeneity.
To better understand neuroblastoma evolutionary diversification
in each patient, clonal hierarchies were reconstructed from SNVs
in biopsies from different time points and spatial distributions of
the disease. We observed both linear and branched evolutionary
trees, creating three to eleven distinct lineages per patient, and
indicating variable clonal diversification across the cohort. Pre-
vious studies13,14 defined four evolutionary trajectories over dif-
ferent anatomic areas for childhood cancers, among them 23
neuroblastomas including two trajectories correlating with poor
outcome. We frequently observed simultaneous subclonal
SCNAs, clonal segmental SCNAs and clonal or subclonal cancer
gene mutations in the same high-risk neuroblastoma, tracing a
clonal sweep as was previously described14. Due to our small
cohort size of 10 patients, correlation with outcome was not
conclusive. In contrast to prior reports14, our allele-specific SCNA
analysis detected clinically relevant 1p and 11q losses as mostly
clonal while in one of three cases with MYCN amplifications, the
amplification was not clonally persistent but occurred later during
the course of disease. Taken together, the high degree of both
spatial and temporal neuroblastoma heterogeneity and the mul-
tiple evolutionary trajectories observed to date in individual
patients with neuroblastoma indicate that many complex routes
culminate in severe neuroblastoma courses and will require
detailed and precise molecular analyses in further patients to
completely understand causal or key points in the process and to
base second-line treatment selection on reliable molecular data
for every individual patient.
To uncover the evolutionary processes of metastasis, we ana-
lysed synchronously resected primary tumour samples and
metastatic infiltrations. Both SCNA and SNV data indicated
branching of the metastatic clone during disease progression
and divergent evolutionary trajectories, with clear evidence of
clonal aberrations within the metastasis that were absent in the
primary tumour. This was verified by MSAI events on chromo-
some 9q, allele-specific LOH or MYCN amplifications that dif-
fered between the metastases and matched primary tumours. In
contrast, Karlsson et al.14 found that synchronous metastasis
mirrored the primary tumour. Branching of the metastatic clone
and substantial heterogeneity between a metastasis and primary
tumour may explain why neuroblastoma relapses often occur at
metastatic sites while primary tumours are successfully eradicated
by surgery and first-line chemotherapy. This is also supported by
the high number of de novo mutations in relapse cases in our
cohort, which indicate a major genotypic shift during (metastatic)
recurrence, in line with the previous reports14,26,29. Inferring
evolutionary trajectories from SNV and SCNA data reveals
variable degrees of clonal diversification and an early emergence
of metastatic clones in neuroblastoma.
An UHR group has recently been described based on molecular
determinants3,26 for a new concept of clinical risk stratification of
patients with neuroblastomas. Notably, UHR molecular deter-
minants were not homogenous throughout biopsies from the
same patient in our cohort. This was especially true for patients
CB1003 and CB1008, whose samples showed extensive temporal
SNV and SCNA heterogeneity. Distinguishing UHR from HR
disease may have important clinical consequences, since UHR
patients have poor outcomes and may benefit from an earlier
switch to alternative treatment approaches55. Based on our
observation of spatial and temporal genetic heterogeneity of UHR
and HR determinants in individual neuroblastoma cases, we
believe that precise risk stratification can only be obtained
through molecular characterisation of neuroblastomas at
diagnosis, resection and recurrence. Our in-depth analysis of
neuroblastoma intratumour heterogeneity reveals that extensive
genetic heterogeneity and subclonal diversification evolves under
therapy and may have important implications for the clinical
interpretation of molecular diagnostic results and for the selection
of appropriate second-line treatment approaches.
Methods
Sample collection. Tumour specimens were collected from 10 patients enrolled
between 2014 and 2018 in the German Society for Pediatric Oncology and
Hematology (GPOH) NB2004 trial or NB registry 2016, and treated at the Charité
University Medicine Berlin (Germany) according to the trial/registry protocols. All
patients and/or their guardians gave written consent for the use of biosamples and
clinical data for research in accordance with the local ethics review board of the
medical faculty, University of Cologne as the trial sponsor of the NB2004 and the
NB registry 2016 (https://clinicaltrials.gov/NCT03042429). Samples were collected
by open surgical biopsy either at diagnosis, at tumour resection after 4–6 cycles of
chemotherapy (according to neuroblastoma therapy regimen) or at diagnosis of
relapse. Fresh samples were immediately snap-frozen in liquid nitrogen and stored
at −80 °C. Portions of tumour material were formalin-fixed and paraffin-
embedded (FFPE) in parallel for diagnostics and preservation in the pathology unit.
Two to 30 biopsies were taken from geographically separate areas of the tumour
body with a minimal distance of 10 mm from each single tumour. From these
biopsies, only tumour regions with high tumour cell content (>60% for WES and
RNA sequencing, 10% for targeted re-sequencing) were included. A pathologist
confirmed the diagnosis and assigned tumour regions for macrodissection with a
high content of vital tumour cells on sequential hematoxylin and eosin-stained
sections. Peripheral blood collected from each patient was used as a matched
germline control for tumour samples. DNA was prepared using the Qiagen DNA
Mini kit according to the manufacturer’s instructions.
Compiling a list of relevant cancer genes. A list of genes potentially involved in
neuroblastoma development was compiled by combining lists of potential cancer
driver genes from several sources: the COSMIC database27 (version 80), a recent
review of the mutational landscape in neuroblastoma10, pan-cancer studies of
paediatric tumours8,16 and a pan-cancer study of adult cancers28. The final list
consisted of 801 genes.
Whole-exome sequencing (WES). The SureSelect Human All Exon V6 kit
(Agilent) was used to prepare libraries enriched with exonic sequences. The
libraries were further prepared for sequencing using the Illumina TruSeq Exome
Kit and sequenced on Illumina HiSeq 2500 and Illumina NextSeq sequencers.
Raw data generation and quality control. Read sequences and base quality scores
were de-multiplexed and stored in Fastq format using the Illumina bcl2fastq (2.16)
software. Adapter remnants and low-quality read ends were trimmed off using
custom scripts. The quality of sequence reads was assessed using FastQC (0.11.5)
software. All libraries were deemed of high quality and usable for follow-up
analyses.
Alignment and coverage evaluation. Reads were aligned to the human genome
(assembly GRCh38) using bwa mem (0.7.17) software56. Duplicate read alignments
were marked using samblaster (0.1.24), and resulting Bam files were stored for later
analyses. Overlap with exon target regions was assessed using the BedTools (2.27.0)
suite of tools and the target region file provided with the SureSelect Human All
Exon V6 kit (Agilent). Mean coverage was computed from these results as the
average number of aligned reads per base in the specified exonic target region as
were the exact proportions of targeted bases covered by each number of aligned
reads. Median coverage was 346× (range: 163×–636×). Aligned reads were further
filtered using sambamba (0.6.8) software to remove the secondary and failed
alignments and PCR-duplicate reads.
Somatic variant calling. We determined somatic single-nucleotide variants
(SNVs) and short insertions/deletions (InDels) using EBCall (2) software57.
Hereby, each tumour sample is first compared to the matching control sample, and
SNVs and InDels supported by a sufficient fraction (≥10%) of aligned reads in the
tumour sample and not exceeding a specific fraction of reads in the control sample
(<5%) are selected as candidate variants. Based on the complete set of control
samples from all patients, a probabilistic model for base mismatches due to
technical reasons was constructed, and only candidate variants deemed highly
unlikely (p < 0.001) under this model, and thus, more likely to have arisen from
biology rather than technical artifacts are considered as somatic variants. A SNV
was considered to be clonal if present in all tumour cells with variant allele fre-
quency greater than 10%, based on the assumption that all somatic mutations were
heterozygous and tumour cell content in the sample was ~60%. The threshold was
adjusted accordingly for SNVs in regions with copy-number gains and losses.
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Annotation of somatic variants. The effect that each putative somatic variant
would have on genes/proteins was annotated using SnpEff (4.3t) software58 and the
knownGene gene annotation from the UCSC genome browser for the hg38
assembly. For each variant, genes potentially affected by the mutation including
effects on the protein level were stored together with information including whe-
ther the variant had been previously detected and deposited in a variant database
such as dbSNP. A smaller list of variants predicted to affect well-known cancer
genes was generated that only included non-silent variants in genes contained in
the list of cancer-relevant genes described above.
ALK mutation detection using droplet digital PCR (ddPCR). The ALK R1275Q
(3824, G>A) hotspot mutation and corresponding wild-type ALK sequence was
detected using the QX200 Droplet Digital PCR System (Bio-Rad Laboratories,
Munich, Germany). The AluI restriction enzyme (5 U, New England Biolabs,
Frankfurt/Main, Germany) was added to each ddPCR reaction to fragment the
tumour DNA59. Reaction mixtures for duplexed TaqMan ddPCR used 2× ddPCR
Supermix for Probes, no dUTP (Bio-Rad Laboratories) and primers/probes adapted
from Combaret et al.60, and have been previously described61. Primers and probes
had the following sequences: ALK1275-for, 5′-GTCCAGGCCCTGGAAGAG-3′;
ALK1275-rev, 5′-GGGGTGAGGCAGTCTTTACTC-3′; ALKR1275Q probe, FAM, 5′-
FAM-TTCGGGATGGCCCAAGACAT-BHQ1-3′ and ALK1275 probe, HEX, 5′-
HEX-TTCGGGATGGCCCGAGACAT-BHQ1-3′. Manufacturer recommendations
for the QX200 Droplet Generator were followed to create droplets, and reaction
endpoints were assessed in the QX200 ddPCR Droplet Reader. The fraction of
mutant allele was identified using QuantaSoft Analysis software, version 1.7.4.0917.
Appropriate non-template, positive and negative controls were included in each
ddPCR assay run for software-based generation of specific thresholds. The model
of Armbruster and Pry62 was followed to calculate (using Bio-Rad look-up tables)
the false-positive rate (FPR) and detection limit for point mutation analysis. FPR
calculation for the point mutation has been previously described61, and was based
in principle on the minimally required mutant target molecule concentration
(copies/µl) and number of false-positive droplets. When the number of droplets
detecting the mutation and the mutant target molecule concentration (copies/µl)
were both above the thresholds that were set, a sample was scored as positive.
Detection limit was determined as previously described61.
Determining allele-specific somatic copy-number alterations. WES read counts
from all neuroblastoma and matched germline (blood) samples were aggregated at
20,180,418 common germline variants from the NCBI dbSNP database using
samtools mpileup (1.9). Variants were removed that (i) were in highly variable
regions of the major histocompatibility complex (MHC, chromosome 6:
28,510,120–33,480,577), (ii) were in positions characterised as not uniquely map-
pable by the UCSC Genome Browser annotation tracks (hoffmannMappability,
k100.Unique.Mappability.bb)63 and (iii) with <20 reads across both neuro-
blastoma/germline samples. Average genome-wide GC content was calculated in
50 bp windows using sequenza-utils gc_wiggle64. Read counts and GC content were
forwarded to Sequenza (v3.0.0)64 for segmentation and calling of allele-specific
SCNAs in each biosample. Segmentations were combined for samples from each
patient using a joint consistent segmentation approach as previously described23,25.
The jointly segmented allele-specific SCNAs then underwent multi-region refer-
ence phasing using refphase25 to determine haplotype-specific SCNAs and detect
MSAI events indicative of parallel evolution. All haplotype-specific SCNA profiles
were manually reviewed and individual mis-segmentations and erroneous sample
purity and ploidy estimates were adjusted accordingly. Haplotype-specific SCNA
profiles were then used to infer tumour evolution and reconstruct ancestral gen-
omes using MEDICC231,32.
Targeted sequencing. A set of 1479 SNVs were selected from exome sequencing
data for targeted sequencing at higher read coverage and in additional samples.
This set included all SNVs in cancer-related genes (from our constructed list,
Supplementary Data 1) and SNVs present in all patients to ensure that each patient
had a minimum number of specific SNVs represented in the targeted sequencing
panel. A custom targeted kit (Agilent) was used to enrich DNA from the genomic
positions of these 1479 sites. DNA was isolated from 150 samples from the 10
patients, subjected to the targeted DNA enrichment, and sequencing libraries were
generated for Illumina HiSeq and NextSeq sequencing (150 nt single-end reads).
Reads were aligned to the human genome (assembly GRCh38) using bwa mem
software56. Variant allele frequencies for each of the 1479 SNVs in each sample
were computed using the Rsamtools Bioconductor/R package.
Reconstruction of clonality trees. The sciClone software (version 1.1.)65 was
used to infer clonal composition and possible neuroblastoma phylogeny in each
patient. This method uses a Bayesian mixture modelling approach to stratify
variants into clusters based on their copy number and variant allele frequency
(VAF) in each sample. Sample tumour purity is estimated from the VAF dis-
tribution in copy-number neutral regions and used to scale all VAFs. The soft-
ware setting, binomial-mixture model was used to cluster VAFs, with an upper
limit set to 20 potential clusters and the default settings for other parameters.
VAFs of exactly 0 were replaced by a very low number (10−10) prior to running
the algorithm, since the clustering algorithm did not converge in extreme cases in
which too many VAF entries were exactly 0. Variant clusters from sciClone were
assigned to clones, and parental relationships between clones were inferred as
follows. Clusters with high cellular fraction (>90%) in all samples were merged
into the founding clone to make up the branch of the tree. Other clusters were
grouped according to their cellular fraction in subsets of samples and assigned as
clones to the branches of the tree, with the requirement that the ancestor clone
was present in the same and potentially more samples. Clusters only present in a
single sample were merged into clones that made up the leaves of the tree. Clones
with a cellular fraction of <5% in a sample were not assigned to the respective
sample. Samples were annotated in the tree at the relevant clone furthest away
from the tree stem, indicating that the sample contained the respective clone and
all of its ancestor clones. Clones were denoted as numbers, branch lengths cor-
responded to the total numbers of SNVs in each clone and cancer-relevant genes
contained in each clone were annotated at the branches. For patients CB1005 and
CB1006, the total numbers of SNVs with median VAFs >0 were too low to infer
meaningful clonality trees.
RNA sequencing. Sufficiently high-quality RNA was available for 48 of 51 samples
used for exome sequencing. RNA was prepared from areas with high tumour cell
content macrodissected from cryosections. RNA was isolated using the NucleoSpin
RNA kit (Machery&Nagel) according to the manufacturer’s protocol. Sequencing
libraries were prepared at the Berlin Institute of Health Sequencing Core using the
standard TrueSeq stranded poly-A enrichment protocol. Libraries were sequenced on
an Illumina HiSeq sequencer as 2 × 75nt paired-end reads. After de-multiplexing, raw
read sequences in Fastq format were aligned to the human genome (assembly hg38)
and Gencode transcript annotation (version 26)66 using STAR alignment software67.
Gene expression was determined as read counts per gene using the featureCounts tool
in subread software. All further analyses of read-count data were performed using the
DESeq2 Bioconductor/R package68. The list of the 104 genes separating neuroblastoma
risk groups was generated by analysing publicly available data from 498 primary
neuroblastomas44 for differential gene expression between high- and low-risk tumours
using the limma R package. Genes with an absolute log2-fold change >1 and a gene-wise
false-discovery rate (q) < 0.1 were considered to be significant in this analysis and
retained in the final list. Expression of these genes in our patient samples was used for
the second principal component analysis.
Detection of MYCN copy number by SNP array and by FISH. For validation of
WES-based estimation of MYCN copy numbers, a SNP array (Cytoscan HD,
ThermoFisher Scientific, #901835) was performed for selected patient samples as in
ref. 15. CEL files with intensity probe signals were analysed using the Chromosome
Analysis Suite (ChAS) software version 4.1.0.90 (r29400) and converted to CYCHP
files. Copy numbers are visualised using the allele difference plot, weighted log2
ratio and the smoothed signal. The smoothed signal is used to directly estimate
copy numbers.
MYCN copy number was detected on FFPE tissue on single-cell level using
FISH analysis. The hybridisation probe XLMYCN amp (MetaSystems) consists of a
green-labelled probe hybridising to the MYCN gene region at 2p24 and an orange-
labelled probe hybridising to the NMI gene region at 2q23 as reference. Data
interpretation was done according to INRG Biology guidelines69.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Raw sequencing data used in this study are available in the European Genome phenome
archive (www.ebi.ac.uk/ega/) under the accession number EGAS00001004735 under the
following dataset IDs: EGAD00001008020 (WES), EGAD00001008156 (targeted re-
sequencing), EGAD00001008133 (RNA-Seq) and EGAD00010002225 (SNP array).
Download of all datasets are available by contacting the study affiliated Data Access
Committee (DAC) via EGA. For WES analysis, NCBI dbSNP (https://
www.ncbi.nlm.nih.gov/snp) and UCSC Genome Browser (https://genome.ucsc.edu/)
were used to aggregate somatic mutations. For defining cancer-related genes, public data
was downloaded from COSMIC database (https://cancer.sanger.ac.uk). For MES/ADRN
differentiation subsets, analyses were done based on datasets downloaded from GEO
(www.ncbi.nlm.nih.gov/geo/) under accession number GSE90805. For analysis of
differential gene expression between high- and low-risk tumours, datasets were
downloaded from GEO with accession GSE49711.
Code availability
Source code in R for running sciClone and for constructing the clonality trees is included
as a zipped file in the supplementary online information (Supplementary Software 1).
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